Publicacións en colaboración con investigadores/as de Instituto de Investigación Sanitaria Hospital 12 de Octubre (12)

2024

  1. Discovery of Thiophene Derivatives as Potent, Orally Bioavailable, and Blood-Brain Barrier-Permeable Ebola Virus Entry Inhibitors

    Journal of Medicinal Chemistry, Vol. 67, Núm. 18, pp. 16381-16402

  2. HIV-1 Reverse Transcriptase Error Rates and Transcriptional Thresholds Based on Single-strand Consensus Sequencing of Target RNA Derived From In Vitro-transcription and HIV-infected Cells

    Journal of Molecular Biology, Vol. 436, Núm. 22

2023

  1. Cell type dependent stability and virulence of a recombinant SARS-CoV-2, and engineering of a propagation deficient RNA replicon to analyze virus RNA synthesis

    Frontiers in Cellular and Infection Microbiology, Vol. 13

  2. Cross neutralization of SARS-CoV-2 omicron subvariants after repeated doses of COVID-19 mRNA vaccines

    Journal of Medical Virology, Vol. 95, Núm. 1

  3. Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2

    Advanced Science, Vol. 10, Núm. 34

  4. Immune Response Against SARS-CoV-2 Infection and Vaccination in a CD8α-Deficient Patient

    Journal of Clinical Immunology

  5. N′-Phenylacetohydrazide Derivatives as Potent Ebola Virus Entry Inhibitors with an Improved Pharmacokinetic Profile

    Journal of Medicinal Chemistry, Vol. 66, Núm. 8, pp. 5465-5483

  6. Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters

    Frontiers in Immunology, Vol. 14

2022

  1. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses

    Frontiers in Immunology, Vol. 13

  2. First confirmation of importation and transmission in Spain of the newly identified SARS-CoV-2 B.1.1.7 variant

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 40, Núm. 10, pp. 546-549

  3. Potent Neutralizing Activity of Polyclonal Equine Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern

    The Journal of infectious diseases, Vol. 227, Núm. 1, pp. 35-39

2020

  1. Prevalence and Clinical Manifestations of Congenital Cytomegalovirus Infection in a Screening Program in Madrid (PICCSA Study)

    Pediatric Infectious Disease Journal, Vol. 39, Núm. 11, pp. 1050-1056